Enterprise Value

28.34M

Cash

3.631M

Avg Qtr Burn

-7.388M

Short % of Float

0.71%

Insider Ownership

1.65%

Institutional Own.

6.77%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
XACIATO (DARE-BV1) Details
Bacterial infection

Approved

Quarterly sales

Ovaprene® Details
Contraceptive

Phase 3

Data readout

Sildenafil Cream, 3.6% Details
Sexual desire disorder, Sexual dysfunction

Phase 3

Initiation

Phase 2

Initiation

DARE-PDM1 Details
Primary dysmenorrhea

Phase 1

Update

DARE-PTB1 Details
Preterm birth

Phase 1

Initiation

IND

Submission